medwireNews: Brodalumab has demonstrated efficacy and appears tolerable for the treatment of axial spondyloarthritis (axSpA), delegates were told at the EULAR 2019 congress in Madrid, Spain.
The phase III study, conducted in South Korea, Taiwan, and Japan, involved 159 patients with non-radiographic axSpA or ankylosing spondylitis, who were randomly assigned to receive the interleukin (IL)-17A inhibitor brodalumab 210 mg subcutaneously or placebo at weeks 1 and 2, and every 2 weeks thereafter.
In all, 77 patients taking brodalumab and 69 taking placebo completed the first 16 weeks of treatment. The ASAS40 response rate at this point was significantly higher among the patients taking brodalumab than those taking placebo, at around 48% versus about 20%. The same was true for ASAS20 response, with corresponding rates of about 70% versus 48%.
The efficacy benefit with brodalumab was consistent in both patients with ankylosing spondylitis and those with non-radiographic axSpA, noted James Cheng-Chung Wei, from Chung Shan Medical University Hospital in Taiwan, China.
Brodalumab was also superior to placebo irrespective of whether patients had previously taken tumor necrosis factor (TNF) inhibitors or not, whether they were HLA-D27 negative or positive, and whether their C-reactive protein levels were above or below the upper limit of normal.
There were no new treatment-related adverse events with brodalumab and the profile was similar to that of placebo, with rates of 32.5% and 25.3%, respectively. The most common adverse event was nasopharyngitis, seen in 11.1% of brodalumab-treated patients and 10.3% of those given placebo.
“Brodalumab will be a potential novel treatment option in patients with axSpA as well as other IL-17A blockers like secukinumab and ixekizumab,” Wei concluded.
By Lucy Piper
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group
- BE AGILE: Bimekizumab shows promise for ankylosing spondylitis
- IBD ‘uncommon’ in patients treated with secukinumab
- Further evidence for the benefits of secukinumab in AS patients